Skip to main content
HLB PANAGENE Co., LTD. logo

HLB PANAGENE Co., LTD. — Investor Relations & Filings

Ticker · 046210 ISIN · KR7046210001 KO Professional, scientific and technical activities
Open in API
Filings indexed 266 across all filing types
Latest filing 2026-03-05 Capital/Financing Update
Country KR South Korea
Listing KO 046210

About HLB PANAGENE Co., LTD.

https://www.hlbpanagene.com/

HLB PANAGENE is a molecular diagnostics company specializing in proprietary Peptide Nucleic Acid (PNA) technology. The company develops, manufactures, and supplies a range of in vitro diagnostic (IVD) products for personalized medicine, with a focus on oncology and infectious diseases. Its portfolio includes diagnostic solutions for various cancers, such as lung, colorectal, and thyroid, by detecting key genetic mutations. The company also offers real-time PCR-based kits for infectious agents like HPV and STIs. Leveraging its PNA platform for high accuracy and rapid analysis, HLB PANAGENE provides PNA materials and diagnostic kits to a global market. Through its subsidiary, the company is expanding its capabilities into immunodiagnostics and point-of-care testing.

Recent filings

Filing Released Lang Actions
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding the 'Acquisition of Convertible Bonds before Maturity'. It details specific financial data such as the bond type, acquisition amount, acquisition date, and the source of funds. This type of filing relates to capital structure changes and debt management, which falls under the 'Capital/Financing Update' category.
2026-03-05 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 1% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding the 'Acquisition of Convertible Bonds before Maturity' (전환사채 발행후 만기전 사채 취득). This is a specific corporate action related to capital structure and debt management. Since it details the company's repurchase of its own debt instruments (convertible bonds), it falls under the 'Capital/Financing Update' category, which covers financing activities and capital structure changes.
2026-03-05 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the acquisition of shares by a director (Jin Yang-gon) of HLB Panagene. This is a standard regulatory filing for insider trading/director dealings, which corresponds to the 'Director's Dealing' category.
2026-02-26 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by a major shareholder (HLB Co., Ltd.) and its special related parties in the issuer (HLB Panagene Inc.). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2026-02-25 Korean
주주총회소집결의
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal 'Notice of Convocation of General Meeting of Shareholders' (주주총회소집결의) issued by HLB Panagene. It details the date, location, and agenda items for the upcoming Annual General Meeting (AGM), including the approval of financial statements, election of directors, and remuneration limits. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the meeting and request their participation/votes. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2026-02-24 Korean
주주총회집중일개최사유신고
Regulatory Filings Classification · 1% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the scheduling of a General Meeting of Shareholders on a 'concentrated day' (a date when many companies hold their AGMs). It explains the reasons for this scheduling conflict and provides details on the meeting date and compliance status. Since it is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2026-02-24 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.